Skip to main content
Premium Trial:

Request an Annual Quote

NetGenics to Resell DiscoveryLink Software Under Expanded IBM Partnership

NEW YORK April 26 - IBM and NetGenics said Thursday they have expanded their existing partnership to include an agreement for NetGenics to resell IBM's DiscoveryLink data integration software.

The companies began collaborating in 1999 on the development of DiscoveryLink.

Under the terms of the expanded partnership, NetGenics can integrate DiscoveryLink into its DiscoveryCenter product, as well as redistribute the software on a stand-alone basis. 

Financial terms of the agreement were not disclosed. 

DiscoveryCenter is a life science informatics integration package that combines NetGenics' software components, public and private data sources, and application software with consulting services. 

DiscoveryLink is a middleware tool that merges information from many sources, including public and private databases, and in diverse data formats and file types.  

"This agreement with NetGenics will expand DiscoveryLink's reach and open new doors to information that researchers need to accelerate the development cycle and get new treatments to patients faster," said Caroline Kovac, vice president, IBM Life Sciences, in a statement. 

The companies were not immediately available for comment.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.